Pharmacology of the low-molecular-weight heparins
- 1 June 1998
- journal article
- research article
- Published by Elsevier in American Heart Journal
- Vol. 135 (6) , S329-S335
- https://doi.org/10.1053/hj.1998.v135.90304
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- A Comparison of Recombinant Hirudin with Heparin for the Treatment of Acute Coronary SyndromesNew England Journal of Medicine, 1996
- Hirudin in Acute Myocardial InfarctionCirculation, 1996
- Heparin: Mechanism of Action, Pharmacokinetics, Dosing Considerations, Monitoring, Efficacy, and SafetyChest, 1995
- Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators.Circulation, 1994
- Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial.Circulation, 1994
- Molecular and Cellular Biology of Blood CoagulationNew England Journal of Medicine, 1992
- Low molecular weight heparinBlood, 1992
- HeparinNew England Journal of Medicine, 1991
- A Randomized Controlled Trial of a Low-Molecular-Weight Heparin (Enoxaparin) to Prevent Deep-Vein Thrombosis in Patients Undergoing Elective Hip SurgeryNew England Journal of Medicine, 1986
- Highly active heparin species with multiple binding sites for antithrombinBiochemical and Biophysical Research Communications, 1979